Incorporating novel agents in the treatment of myelodysplastic syndromes

Leukemia Research

Volumn 34, Issue 1, 2010, Pages 6-17

  Anargyrou, Konstantinos ^a   Vassilakopoulos, Theodoros P ^b   Angelopoulou, Maria K ^b   Terpos, Evangelos ^c  

^a 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Azacitidine; Decitabine; Farnesyl transferase inhibitors; Histone deacetylase inhibitors; Hypomethylating agents; Immunomodulatory drugs; Lenalidomide; Myelodysplastic syndrome

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; AZACITIDINE; BEVACIZUMAB; DEFERASIROX; DEFERIPRONE; DNA METHYLTRANSFERASE INHIBITOR; ELTROMBOPAG; ETANERCEPT; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOMODULATING AGENT; IRON CHELATING AGENT; LENALIDOMIDE; LONAFARNIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; ROMIDEPSIN; ROMIPLOSTIM; ROMIPLOSTIN; SNDX 275; THALIDOMIDE; THALOMIDE; TIPIFARNIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANOREXIA; ARTHRALGIA; ARTHRITIS; BILIARY CIRRHOSIS; BLAST CELL; BONE MARROW SUPPRESSION; CELLULITIS; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; CYTOGENETICS; DEMENTIA; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EPISTAXIS; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE DELETION; HEADACHE; HEMATOLOGIC MALIGNANCY; HEMOSIDEROSIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; IRON OVERLOAD; KIDNEY FAILURE; LEG PAIN; LEUKEMIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; MYELOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; PAIN; PALLIATIVE THERAPY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REMISSION; REPEATED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RIGOR; SEDATION; SHOULDER PAIN; SIDE EFFECT; SORE THROAT; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VERTIGO; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 73249124795     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.07.021     Document Type: Review

References (115)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Granlick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 2 (1982) 189-199
2. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 6 (1997) 2079-2088
3. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organization classification of tumours. Pathology and genetics: tumours of hematopoietic and lymphoid tissues (2001), IARC Press, Washington, DC
4. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 23 (2007) 3503-3510
5. Alessandrino E.P., Della Porta M.G., Bacigalupo A., Van Lint M.T., Falda M., Onida F., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112 3 (2008) 895-902
6. Park M.J., Kim H.J., Kim S.H., Kim D.H., Kim S.J., Jang J.H., et al. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol 81 5 (2008) 364-373
7. Breccia M., Cannella L., Stefanizzi C., Latagliata R., Fama A., Santopietro M., et al. WPSS versus simplified myelodysplastic syndrome risk score: which is the best tool for prediction of survival in myelodysplastic patients. Leuk Res 33 7 (2009) e93-e94
8. Sekeres M.A., Stone R.M., Zahrieh D., Neuberg D., Morrison V., De Angelo D.J., et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 18 4 (2004) 809-816
9. Estey E. Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Semin Hematol 32 2 (1995) 132-151
10. Estey E.H., Thall P.F., Cortes J.E., Giles F.J., O'Brien S., Pierce S.A., et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 98 13 (2001) 3575-3583
11. Runde V., de Witte T., Arnold R., Gratwohl A., Hermans J., van Biezen A., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21 12 (1998) 255-261
12. Ho A.Y., Pagliuca A., Kenyon M., Parker J.E., Mijovic A., Devereux S., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104 6 (2004) 1616-1623
13. Kröger N., Schetelig J., Zabelina T., Krüger W., Renges H., Stute N., et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 28 7 (2001) 643-647
14. Molldrem J.J., Leifer E., Bahceci E., Saunthararajah Y., Rivera M., Dunbar C., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137 3 (2002) 156-163
15. Broliden P.A., Dahl I.M., Hast R., Johansson B., Juvonen E., Kjeldsen L., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 91 5 (2006) 667-670
16. Lim Z.Y., Killick S., Germing U., Cavenagh J., Culligan D., Bacigalupo A., et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21 7 (2007) 1436-1441
17. Macdougall I.C. Novel erythropoiesis stimulating protein. Semin Nephrol 20 4 (2000) 375-381
18. Egrie J.C., Dwyer E., Browne J.K., Hitz A., and Lyjos M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31 4 (2003) 290-299
19. Stasi R., Abruzzese E., Lanzetta G., Terroli E., and Amadori S. Darbepoetin-alfa for the treatment of anemic patients with low- and intermediate-1 risk myelodysplastic syndromes. Ann Oncol 16 12 (2005) 1921-1927
20. Giraldo P., Nomdedeu B., Loscertales J., Requena C., de Par R., Tormo M., et al. Darbeotin a for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 107 12 (2006) 2807-2816
21. Gotlib J., Lavori P., Quesada S., Stein R.S., Shahnia S., and Greenberg P.L. A phase II intra-patient dose-escalation trial of weight-based Darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 84 1 (2009) 15-20
22. Gabrilove J., Paquette R., Lyons R.M., Mushtaq C., Sekeres M.A., Tomita D., et al. Phase-2, single arm trial to evaluate the effectiveness of Darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 142 3 (2008) 379-393
23. Moyo V., Lefebvre P., Duh M.S., Yektashenas B., and Mundle S. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 87 7 (2008) 527-536
24. Jädersten M., Malcovati L., Dybedal I., Della Porta M.G., Invernizzi R., Montgomery S.M., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26 21 (2008) 3607-3613
25. Park S., Grabar S., Kelaidi C., Beyne-Rauzy O., Picard F., Bardet V., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111 2 (2008) 574-582
26. Golshayan A.R., Jin T., Maciejewski J., Fu A.Z., Bershadsky B., Kattan M.W., et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 137 2 (2007) 125-132
27. Hellström-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybeval I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120 6 (2003) 1037-1046
28. Greenberg P.L. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 4 1 (2006) 91-96
29. Rose C., Brechignac S., Vassilief D., Beyne-Rauzy O., Stamatoullas A., Larbaa D., et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 110 11 (2007) 80a-81a [abstract]
30. Kasner M.T., and Luger S.M. Update on the therapy for myelodysplastic syndrome. Am J Hematol 84 3 (2009) 177-186
31. Bennett J.M., and MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83 11 (2008) 858-861
32. Hider R.C., and Zhou T. The design of orally active iron chelators. Ann NY Acad Sci 1054 (2005) 141-154
33. Pennell D.J., Berdoukas V., Karagiorga M., Ladis V., Piga A., Aessopos A., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107 9 (2006) 3738-3744
34. Nisbet-Brown E., Olivieri N.F., Giardina P.J., Grady R.W., Neufeld E.J., Séchaud R., et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361 9369 (2003) 1597-1602
35. Porter J., Galanello R., Saglio G., Neufeld E.J., Vichinsky E., Cappellini M.D., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80 2 (2007) 168-176
36. Metzgeroth G., Dinter D., Schultheis B., Dorn-Beineke A., Lutz K., Leismann O., et al. Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study. Ann Hematol 88 4 (2009) 301-310
37. Nick H., Acklin P., Lattmann R., Buehlmayer P., Hauffe S., Schupp J., et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10 12 (2003) 1065-1076
38. Kuter D.J. New thrombopoietic growth factors. Blood 109 11 (2007) 4607-4616
39. Wang B., Nichol J.L., and Sullivan J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76 6 (2004) 628-638
40. Bussel J., Kuter D.J., George J.N., McMillan R., Aledort L.M., Conklin G.T., et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355 16 (2006) 1672-1681
41. Bussel J.B., Kuter D.J., Pullarkat V., Lyons R.M., Guo M., and Nichol J.L. Safety and efficacy of long-term treatment with romiplostin in thrombocytopenic patients with chronic ITP. Blood 113 10 (2009) 2161-2171
42. Kantarjian H.M., Fenaux P., Sekeres M.A., Becker P., Boruchov A.M., Bowen D., et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients with low-risk myelodysplastic syndrome (MDS): update including extended treatment. Blood 110 11 (2007) 81a [abstract]
43. Erickson-Miller C.L., Delorme E., Tian S.S., Hopson C.B., Landis A.J., Valoret E.I., et al. Preclinical activity of Eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 27 2 (2009) 424-430
44. Bussel J.B., Cheng G., Saleh M.N., Psaila B., Kovaleva L., Meddeb B., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 22 (2007) 2237-2247
45. Bussel J.B., Provan D., Shamsi T., Cheng G., Psaila B., Kovaleva L., et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373 9664 (2009) 641-648
46. Bussel J.B., Cheng G., Saleh M.N., Meddeb B., Bailey C., Stone N.L., et al. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura. Blood 112 11 (2008) 1177 [abstract]
47. Will B., Luciano J., Kawahara M., Erickson-Miller C., Verna A., Aivado M., et al. The non-peptide thrombopoietin receptor agonist Eltrombopag (SB-497115, Promacta/Revolade) does not stimulate malignant growth of bone marrow cells from patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Res 33 Suppl. 1 (2009) C026 [abstract]
48. Sorm F., Piskala A., Cihak A., and Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 20 4 (1964) 202-203
49. Jones P.A., and Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20 1 (1980) 85-93
50. Cihak A. Biological effects of 5-azacytidine in eukaryocytes. Oncology 30 5 (1974) 405-422
51. Jones P.A., Taylor S.M., and Wilson V.L. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 84 (1983) 202-211
52. Friedman S. The inhibition of DNA (cytosine-5) methylases by 5-azacytidine. The effect of azacytosine-containing DNA. Mol Pharmacol 19 2 (1981) 314-320
53. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20 10 (2002) 2429-2440
54. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24 24 (2006) 3895-3903
55. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10 3 (2009) 223-232
56. Sorm F., and Vesely J. Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15 4 (1968) 339-343
57. Momparler R.L. Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin Hematol 42 3 Suppl. 2 (2005) S9-S16
58. Rivard G.E., Momparler R.L., Demers J., Benoit P., Raymond R., Lin K., et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5 6 (1981) 453-462
59. Chabot G.G., Rivard G.E., and Momparler R.L. Plasma and cerebrospinal fluid pharmacokinetics of 5-aza-2′-deoxycytidine in rabbits and dogs. Cancer Res 43 2 (1983) 592-597
60. Cashen A., Shah A., Helget A., Todt L., Fisher N., and DiPersio J. A phase I pharmacokinetic trial of decitabine administered as a 3-hour infusion to patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Blood 106 11 (2005) 527a-528a [abstract]
61. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 8 (2006) 1794-1803
62. Kantarjian H.M., O'Brien S., Huang X., Garcia-Manero G., Ravandi F., Cortes J., et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109 6 (2007) 1133-1137
63. Wijermans P., Suciu S., Baila L., Platzbecker U., Giagounidis A., Selleslag D., et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS study groups. Blood 112 11 (2008) 90 [abstract]
64. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 1 (2007) 52-57
65. Rosato R.R., and Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 9 4 (2005) 809-824
66. Gore S.D., Weng L.J., Figg W.D., Zhai S., Ross C., Donehower R.C., et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 8 4 (2002) 963-970
67. Kuendgen A., Strupp C., Aivado M., Bernhardt A., Hildebrandt B., Haas R., et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104 5 (2004) 1266-1269
68. Pilatrino C., Cilloni D., Messa E., Morotti A., Giugliano E., Pautasso M., et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 104 1 (2005) 101-109
69. Kuendgen A., Knipp S., Fox F., Strupp C., Hildebrandt B., Steidl C., et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 84 1 (2005) 61-66
70. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109 7 (2007) 2781-2790
71. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112 4 (2008) 981-989
72. Nakajima H., Kim Y.B., Terano H., Yoshida M., and Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241 1 (1998) 126-133
73. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14 3 (2008) 826-832
74. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 3 (2008) 1060-1066
75. Reuter C.W., Morgan M.A., and Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 96 5 (2000) 1655-1669
76. Rowinsky E.K., Windle J.J., and Von Hoff D.D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17 11 (1999) 3631-3652
77. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61 1 (2001) 131-137
78. Kurzrock R., Kantarjian H.M., Cortes J.E., Singhania N., Thomas D.A., Wilson E.F., et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102 13 (2003) 4527-4534
79. Kurzrock R., Albitar M., Cortes J.E., Estey E.H., Faderl S.H., Garcia-Manero G., et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22 7 (2004) 1287-1292
80. Fenaux P., Raza A., Mufti G.J., Aul C., Germing U., Kantarjian H., et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 109 10 (2007) 4158-4163
81. Feldman E.J., Cortes J., DeAngelo D.J., Holyoake T., Simonsson B., O'Brien S.G., et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 22 9 (2008) 1707-1711
82. Ravoet C., Mineur P., Robin V., Debusscher L., Bosly A., André M., et al. Farnesyltransferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol 87 11 (2008) 881-885
83. Bartlett J.B., Tozer A., Stirling D., and Zeldis J.B. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93 6 (2005) 613-619
84. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98 4 (2001) 958-965
85. Musto P., Falcone A., Sanpaolo G., Bisceglia M., Matera R., and Carella A.M. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica 87 8 (2002) 884-886
86. Strupp C., Germing U., Aivado M., Misgeld E., Haas R., and Gattermann N. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16 1 (2002) 1-6
87. Moreno-Aspitia A., Geyer S., Li C.Y., Tefferi A., Witzig T., Niedrinhaus R.D., et al. Multicenter phase II trial of thalidomide (thal) in adult patients with myelodysplastic syndromes (MDS). Blood 100 (2002) 96a [abstract]
88. Christian M.S., Laskin O.L., Sharper V., Hoberman A., Stirling D.I., and Latriano L. Evaluation of the developmental toxicity of lenalidomide in rabbits. Birth Defects Res B Dev Reprod Toxicol 80 3 (2007) 188-207
89. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 6 (2005) 549-557
90. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 14 (2006) 1456-1465
91. List A.F., Wride K., Dewald G.W., Bennett J.M., Giagounidis A., Kurtin S., et al. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion. Leuk Res 31 Suppl. 1 (2007) S38
92. Raza A., Reeves J.A., Feldman E.J., Dewald G.W., Bennett J.M., Deeg H.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111 1 (2008) 86-93
93. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A., et al. A role for tumor necrosis factor-a, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103 1 (1998) 176-188
94. Deeg H.J., Gotlib J., Beckham C., Dugan K., Holmberg L., Schubert M., et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 16 2 (2002) 162-164
95. Maciejewski J.P., Risitano A.M., Sloand E.M., Wisch L., Geller N., Barrett J.A., et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 117 1 (2002) 119-126
96. Raza A., Candoni A., Khan U., Lisak L., Tahir S., Silvestri F., et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45 10 (2004) 2099-2104
97. Boula A., Voulgarelis M., Giannouli S., Katrinakis G., Psyllaki M., Pontikoglou C., et al. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res 12 10 (2006) 3099-3108
98. Giles F.J., Stopeck A.T., Silverman L.R., Lancet J.E., Cooper M.A., Hannah A.L., et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102 3 (2003) 795-801
99. Gotlib J., Jamieson C.H.M., List A., Cortes J., Albitar M., Sridhar K., et al. Phase II study of Bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): preliminary results. Blood 102 (2003) 425a [abstract]
100. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven disease. Cytokine Growth Factor Rev 15 4 (2004) 229-235
101. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347 7 (2002) 481-487
102. Bonati A., Rizzoli V., and Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 7 6 (2006) 397-405
103. Schiller G.J., Slack J., Hainsworth J.D., Mason J., Saleh M., Rizzieri D., et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 24 16 (2006) 2456-2464
104. Vey N., Bosly A., Guerci A., Feremans W., Dombret H., Dreyfus F., et al. Arsenic trioxide in myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 24 16 (2006) 2465-2471
105. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., et al. Regulation of JNK signaling by GSTp. EMBO J 18 5 (1999) 1321-1334
106. Ruscoe J.E., Rosario L.A., Wang T., Gaté L., Arifoglu P., Wolf C.R., et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 298 1 (2001) 339-345
107. Gaté L., Lunk A., and Tew K.D. Resistance to phorbol 12-myristate 13-acetate-induced cell growth arrest in an HL60 cell line chronically exposed to a glutathione S-transferase pi inhibitor. Biochem Pharmacol 65 10 (2003) 1611-1622
108. Raza A., Callander N., Ochoa L., Piro L., Emanuel P., Guba S., et al. Hematologic Improvement (HI) by TLK199 (Telintra™), a novel glutathione analog, in myelodysplastic syndrome: phase 2 study results. Blood 106 11 (2005) 708a [abstract]
109. Milella M., Kornblau S.M., and Andreeff M. The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 7 2 (2003) 160-190
110. Navas T.A., Mohindru M., Estes M., Ma J.Y., Sokol L., Pahanish P., et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 108 13 (2006) 4170-4177
111. Serova M., Galmarini C.M., Ghoul A., Benhadji K., Green S.R., Chiao J., et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells. Br J Cancer 97 5 (2007) 628-636
112. Plunkett W., Garcia-Manero G., Faderl S., Cortes J., Boone P., Hilbe C., et al. Phase I study of sapacitabine, an oral nucleoside analogue, in patients with advanced leukemias or myelodysplastic syndromes. J Clin Oncol 25 18S (2007) 7063 [abstract]
113. Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., et al. NF-kB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107 3 (2006) 1156-1165
114. Terpos E., Verrou E., Banti A., Kaloutsi V., Lazaridou A., and Zervas K. Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. Leuk Res 31 4 (2007) 559-562
115. Nachtkamp K., Kündgen A., Strupp C., Giagounidis A., Kobbe G., Gattermann N., et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leuk Res 33 8 (2009) 1024-1028